Maximum Views Reached

You have reached the maximum number of Guideline views for today. By creating a free account, you can increase your number of complimentary daily views.

To view this Guideline, please log in to your account. If you do not have an account, you can create one for free by clicking the button below.

Castration-Resistant Prostate Cancer

Publication Date: December 1, 2018

Last Updated: March 14, 2022

Guideline Statements

Asymptomatic non-metastatic CRPC

1. Clinicians should offer apalutamide or enzalutamide with continued androgen deprivation to patients with non-metastatic CRPC at high risk for developing metastatic disease. (Standard, A)

Castration-Resistant Prostate Cancer

Guideline Statements

Asymptomatic non-metastatic CRPC

Overview

Title

Authoring Organization